55 112

Cited 1 times in

Efficacy and Safety of Guideline-Recommended Risk Score-Directed Dual Antiplatelet Therapy After 2nd-Generation Drug-Eluting Stents

DC FieldValueLanguage
dc.contributor.author고영국-
dc.contributor.author권혁문-
dc.contributor.author김병극-
dc.contributor.author김중선-
dc.contributor.author신동호-
dc.contributor.author이병권-
dc.contributor.author장양수-
dc.contributor.author최동훈-
dc.contributor.author홍명기-
dc.contributor.author홍성진-
dc.contributor.author안철민-
dc.date.accessioned2020-02-26T06:45:41Z-
dc.date.available2020-02-26T06:45:41Z-
dc.date.issued2020-
dc.identifier.issn1346-9843-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/175277-
dc.description.abstractBACKGROUND: Evaluate the safety and efficacy of guideline-recommended risk score-directed dual antiplatelet therapy (GD-DAPT) based on THE PRECISE-DAPT score after 2nd-generation drug-eluting stent (DES) implantation.Methods and Results:We analyzed 5,131 patients pooled from 4 clinical trials. Patients were divided into 3 groups according to current recommendations on the duration of DAPT and their actual DAPT duration: GD-DAPT (n=2,183), shorter DAPT (n=1,540), longer DAPT (n=1,408). The primary endpoint was the rate of net adverse clinical events (NACE) during the first 12 months. The secondary endpoints were ischemic or bleeding events. Overall, GD-DAPT did not affect NACE (1.2% vs. 1.2% for shorter DAPT and 1.7% for longer DAPT) or bleeding events (0.6% vs. 0.5% and 0.9%), and there were fewer ischemic events (2.8% vs. 4.4% and 4.0%, P=0.03) than with shorter DAPT. Especially in acute coronary syndrome (ACS) patients, GD-DAPT had fewer NACE (1.5% vs. 1.4% and 4.2%; P=0.006) and bleeding events (0.8% vs. 0.5% and 2.8%; P=0.001) than longer DAPT as well as fewer ischemic events (2.8% vs. 4.4% and 4.7%; P=0.03) than shorter DAPT. CONCLUSIONS: GD-DAPT did not affect NACE or bleeding events and reduced the number of ischemic events at 12 months compared with shorter DAPT. For ACS, GD-DAPT was associated with favorable outcomes compared with non-GD-DAPT. Therefore, GD-DAPT may optimize efficacy and safety.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish, Japanese-
dc.publisherJapanese Circulation Society-
dc.relation.isPartOfCIRCULATION JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleEfficacy and Safety of Guideline-Recommended Risk Score-Directed Dual Antiplatelet Therapy After 2nd-Generation Drug-Eluting Stents-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorJi-Yong Jang-
dc.contributor.googleauthorByoung-Kwon Lee-
dc.contributor.googleauthorJung-Sun Kim-
dc.contributor.googleauthorDong-Ho Shin-
dc.contributor.googleauthorSung-Jin Hong-
dc.contributor.googleauthorChul-Min Ahn-
dc.contributor.googleauthorByeong-Keuk Kim-
dc.contributor.googleauthorYoung-Guk Ko-
dc.contributor.googleauthorDonghoon Choi-
dc.contributor.googleauthorMyeong-Ki Hong-
dc.contributor.googleauthorKyung Woo Park-
dc.contributor.googleauthorHyeon-Cheol Gwon-
dc.contributor.googleauthorHyo-Soo Kim-
dc.contributor.googleauthorHyuck Moon Kwon-
dc.contributor.googleauthorYangsoo Jang-
dc.identifier.doi10.1253/circj.CJ-19-0667-
dc.contributor.localIdA00127-
dc.contributor.localIdA00260-
dc.contributor.localIdA00260-
dc.contributor.localIdA00493-
dc.contributor.localIdA00493-
dc.contributor.localIdA00961-
dc.contributor.localIdA00961-
dc.contributor.localIdA02097-
dc.contributor.localIdA02097-
dc.contributor.localIdA05648-
dc.contributor.localIdA05648-
dc.contributor.localIdA02793-
dc.contributor.localIdA02793-
dc.contributor.localIdA03448-
dc.contributor.localIdA03448-
dc.contributor.localIdA04053-
dc.contributor.localIdA04053-
dc.contributor.localIdA04391-
dc.contributor.localIdA04391-
dc.contributor.localIdA04403-
dc.contributor.localIdA04403-
dc.relation.journalcodeJ00534-
dc.identifier.eissn1347-4820-
dc.identifier.pmid31839621-
dc.subject.keywordDrug-eluting stent-
dc.subject.keywordDual antiplatelet duration-
dc.subject.keywordPRECISE-DAPT risk score-
dc.contributor.alternativeNameKo, Young Guk-
dc.contributor.affiliatedAuthor고영국-
dc.contributor.affiliatedAuthor권혁문-
dc.contributor.affiliatedAuthor권혁문-
dc.contributor.affiliatedAuthor김병극-
dc.contributor.affiliatedAuthor김병극-
dc.contributor.affiliatedAuthor김중선-
dc.contributor.affiliatedAuthor김중선-
dc.contributor.affiliatedAuthor신동호-
dc.contributor.affiliatedAuthor신동호-
dc.contributor.affiliatedAuthor이병권-
dc.contributor.affiliatedAuthor이병권-
dc.contributor.affiliatedAuthor장양수-
dc.contributor.affiliatedAuthor장양수-
dc.contributor.affiliatedAuthor최동훈-
dc.contributor.affiliatedAuthor최동훈-
dc.contributor.affiliatedAuthor홍명기-
dc.contributor.affiliatedAuthor홍명기-
dc.contributor.affiliatedAuthor홍성진-
dc.contributor.affiliatedAuthor홍성진-
dc.citation.volume84-
dc.citation.number2-
dc.citation.startPage161-
dc.citation.endPage168-
dc.identifier.bibliographicCitationCIRCULATION JOURNAL, Vol.84(2) : 161-168, 2020-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.